Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.lungcan.2021.05.019
DC FieldValue
dc.titleThromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis
dc.contributor.authorZhu, Viola W.
dc.contributor.authorZhao, Joseph J.
dc.contributor.authorGao, Yanfei
dc.contributor.authorSyn, Nicholas L.
dc.contributor.authorZhang, Shannon S.
dc.contributor.authorOu, Sai-Hong Ignatius
dc.contributor.authorBauer, Kenneth A.
dc.contributor.authorNagasaka, Misako
dc.date.accessioned2022-10-26T08:34:24Z
dc.date.available2022-10-26T08:34:24Z
dc.date.issued2021-07-01
dc.identifier.citationZhu, Viola W., Zhao, Joseph J., Gao, Yanfei, Syn, Nicholas L., Zhang, Shannon S., Ou, Sai-Hong Ignatius, Bauer, Kenneth A., Nagasaka, Misako (2021-07-01). Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. Lung Cancer 157 : 147-155. ScholarBank@NUS Repository. https://doi.org/10.1016/j.lungcan.2021.05.019
dc.identifier.issn0169-5002
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/233505
dc.description.abstractIntroduction: Increased thromboembolism (TE) has been reported in ALK+ and ROS1+ non-small cell lung cancer (NSCLC). Materials and Methods: Odds ratios (OR) and hazard ratios (HR) of TE were calculated from meta-analysis and time-to-event analysis respectively for either ALK+ or ROS1+ NSCLC patients. Results: We identified eight studies (766 ALK+, 143 ROS1+, 2314 non-ALK+ and non-ROS1+ NSCLC patients) for the meta-analysis. For ALK+ NSCLC, the pooled OR was 2.00 (95% CI: 1.60-2.50) for total TE (TTE) by random-effects model, 2.10 (95% CI: 1.70-2.60) for venous thromboembolism (VTE), and 1.24 (95% CI: 0.80-1.91) for arterial thromboembolism (ATE). For ROS1+ NSCLC, the pooled OR was 3.08 (95% CI: 1.95-4.86) for TTE, and 3.15 (95% CI: 1.83-5.43) for VTE. Six studies (739 ALK+, 137 ROS1+, 561 EGFR+, 714 “wildtype” NSCLC patients) were included in the time-to-event analysis. The TTE incidence rate was 17.4 (95% CI: 15.3-19.5) per 100 pateint-years for ALK+ NSCLC, and 32.1 (95% CI: 24.6-39.6) per 100 patient-years for ROS1+ NSCLC with a 50 % cumulative incidence rate at year 3 of diagnosis. HR for TTE was 2.35 (95% CI: 1.90-2.92, p < 0.001) and 3.23 (95% CI: 2.40-4.34, p < 0.001) for ALK+ and ROS1+ NSCLC, respectively. Comparing ROS1+ NSCLC to ALK+ NSCLC, HR for TTE was 1.37 (95% CI: 1.05-1.79, p = 0.020). Conclusions: ALK+ and ROS1+ NSCLC patients had an increased risk of TE. ROS1+ NSCLC had further increased risk of TE over ALK+ NSCLC. © 2021 The Author(s)
dc.publisherElsevier Ireland Ltd
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2021
dc.subjectALK+ NSCLC
dc.subjectCumulative incidence
dc.subjectDeep vein thrombosis
dc.subjectMeta-analysis
dc.subjectPulmonary embolism
dc.subjectROS1+ NSCLC
dc.subjectSystematic review
dc.subjectThromboembolism
dc.typeArticle
dc.contributor.departmentYONG LOO LIN SCHOOL OF MEDICINE
dc.description.doi10.1016/j.lungcan.2021.05.019
dc.description.sourcetitleLung Cancer
dc.description.volume157
dc.description.page147-155
Appears in Collections:Students Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1016_j_lungcan_2021_05_019.pdf4.67 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons